Citations

Clear

3042 citation(s) found for "Kumar, S".

High-Performance 3D Compressive Sensing MRI Reconstruction Using Many-Core Architectures
Kim, Daehyun , Trzasko, Joshua D. , Smelyanskiy, Mikhail , Haider, Clifton R. , Dubey, Pradeep Kumar , Manduca, Armando

Mayo Clinic

International Journal of Biomedical Imaging | September 15, 2011 | Volume: 2011 | Issue: No issue available | Pages: 1-11

10.1155/2011/473128 | PMID 21922017 Get It

Compressive sensing (CS) describes how sparse signals can be accurately reconstructed from many fewer samples than required by the Nyquist criterion. Since MRI scan duration is proportional to the number of acquired samples, CS has been gaining significant attention in MRI. However, the computationally intensive nature of CS reconstructions has precluded their use in routine clinical practice. In this work, we investigate how different throughput-oriented architectures can benefit one CS algorithm and what levels of acceleration are feasible on different modern platforms. We demonstrate that a CUDA-based code running on an NVIDIA Tesla C2050 GPU can reconstruct a 256 × 160 × 80 volume from an 8-channel acquisition in 19 seconds, which is in itself a significant improvement over the state of the art. We then show that Intel's Knights Ferry can perform the same 3D MRI reconstruction in only 12 seconds, bringing CS methods even closer to clinical viability.
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome
D’Souza, Anita , Hayman, Suzanne R. , Mauermann, Michelle L. , Lacy, Martha Q. , Kyle, Robert A. , Kumar, Shaji , Greipp, Philip R., Lust, John A., Russell, Stephen J. , Zeldenrust, Steven R., Dingli, David , Rajkumar, S. Vincent , Dispenzieri, Angela , Buadi, Francis K. , Gertz, Morie A. , Witzig, Thomas E. , Rajkumar, S Vincent , D'Souza, Anita , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Mauermann, Michelle L

Mayo Clinic

Blood | September 1, 2011 | Volume: 118 | Issue: 17 | Pages: 4663-4665

10.1182/blood-2011-06-362392 | PMID 21881050 Get It

Abstract The POEMS syndrome is associated with elevated vascular endothelial growth factor (VEGF) levels. Several studies have compared serum VEGF levels between POEMS patients and other disease entities showing higher serum VEGF in POEMS syndrome; however, it is unknown whether serum levels are reliable and reproducible given variable platelet release of VEGF. We therefore compared plasma levels of VEGF in 29 patients with POEMS syndrome with those of other disorders (n = 76). We demonstrated that plasma VEGF levels are useful in differentiating POEMS from other plasma cell dyscrasias, neuropathic processes, and multisystem illnesses. Plasma VEGF is also useful in monitoring disease activity after treatment and correlates with clinical improvements better than hematologic response.
A simple statistical model and association rule filtering for classification
Simon, György , Kumar, Vipin , Li, Peter W.

Mayo Clinic

Proceedings of the 17th ACM SIGKDD international conference on Knowledge discovery and data mining | August 31, 2011 | Volume: No volume available | Issue: No issue available | Pages: 823-831

10.1145/2020408.2020550 Get It

Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
Kumar, Shaji , Uno, Hajime , Jacobus, Susanna , Wier, Scott A. Van, Ahmann, Greg, Henderson, Kimberly J., Haug, Jessica, Greipp, Philip R., Fonseca, Rafaël , Rajkumar, S. Vincent , Callander, Natalie S. , Siegel, David S. , Rajkumar, S Vincent , Uno, Hajime , Fonseca, Rafael

Mayo Clinic

Blood | August 23, 2011 | Volume: 118 | Issue: 16 | Pages: 4359-4362

10.1182/blood-2011-03-342089 | PMID 21860025 Get It

Abstract Detection of specific chromosomal abnormalities by FISH and metaphase cytogenetics allows risk stratification in multiple myeloma; however, gene expression profiling (GEP) based signatures may enable more specific risk categorization. We examined the utility of 2 GEP-based risk stratification systems among patients undergoing initial therapy with lenalidomide in the context of a phase 3 trial. Among 45 patients studied at baseline, 7 (16%) and 10 (22%), respectively, were high-risk using the GEP70 and GEP15 signatures. The median overall survival for the GEP70 high-risk group was 19 months versus not reached for the rest (hazard ratio = 14.1). Although the medians were not reached, the GEP15 also predicted a poor outcome among the high-risk patients. The C-statistic for the GEP70, GEP15, and FISH based risk stratification systems was 0.74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475.
Gαi2 and ZAP-70 Mediate RasGRP1 Membrane Localization and Activation of SDF-1–Induced T Cell Functions
Kremer, Kimberly N. , Hedin, Karen E. , Kumar, Ashok

Mayo Clinic

The Journal of Immunology | August 19, 2011 | Volume: 187 | Issue: 6 | Pages: 3177-3185

10.4049/jimmunol.1100206 | PMID 21856938 Get It

Abstract RasGRP1, a Ras guanine-nucleotide exchange factor, critically mediates T cell development and function and controls immunodeficiency and autoimmunity. In this study, we describe a unique mechanism of mobilization and activation of RasGRP1 in response to SDF-1, a chemokine that signals via the G protein-coupled receptor CXCR4. Depletion of RasGRP1 impaired SDF-1–stimulated human T cell migration, expression of the activation marker CD69, and activation of the ERK MAPK pathway, indicating that RasGRP1 mediates SDF-1 functions. SDF-1 treatment caused RasGRP1 to localize to the plasma membrane to activate K-Ras and to the Golgi to activate N-Ras. These events were required for cellular migration and for ERK activation that mediates downstream transcriptional events in response to SDF-1. SDF-1–dependent localization of RasGRP1 did not require its diacylglycerol-binding domain, even though diacyglycerol was previously shown to mediate localization of RasGRP1 in response to Ag stimulation. This domain was, however, required for activity of RasGRP1 after its localization. Intriguingly, SDF-1 treatment of T cells induced the formation of a novel molecular signaling complex containing RasGRP1, Gαi2, and ZAP-70. Moreover, SDF-1–mediated signaling by both Gi proteins and ZAP-70 was required for RasGRP1 mobilization. In addition, RasGRP1 mobilization and activation in response to SDF-1 was dependent on TCR expression, suggesting that CXCR4 heterodimerizes with the TCR to couple to ZAP-70 and mobilize RasGRP1. These results increase understanding of the molecular mechanisms that mediate SDF-1 effects on T cells and reveal a novel mechanism of RasGRP1 regulation. Other G protein-coupled receptors may similarly contribute to regulation of RasGRP1.
Ventral “Spinal Epidural Meningeal Cysts”—Not Epidural and Not Cysts? Case Series and Review of the Literature
Ball, Bret Gene, Mokri, Bahram, Kumar, Neeraj , Piepgras, David G., Luetmer, Patrick H. , Giannini, Caterina

Mayo Clinic

Neurosurgery | August 5, 2011 | Volume: 70 | Issue: 2 | Pages: 320-328

10.1227/neu.0b013e318230968c | PMID 21822155 Get It

Abstract BACKGROUND: Ventral spinal epidural meningeal cysts are rare entities for which the pathogenesis is poorly understood. OBJECTIVE: We present the clinical, radiographic, surgical, and pathologic findings of 4 patients with extensive ventral spinal epidural meningeal cysts and review the relevant literature. In addition, we discuss a suspected mechanism for pathogenesis. METHODS: Four patients with anterior spinal epidural meningeal cysts are retrospectively reviewed. RESULTS: Ventral spinal epidural meningeal cysts are often large, extending on average from C2 to L1 in our series. Patients typically present with a prolonged course of symptoms and signs, including segmental muscle weakness and atrophy, subtle myelopathy, mild to moderate spinal pain, and headache. Histopathologic analysis of the cyst wall demonstrates collagenous tissue consistent with dura but without arachnoid features. Dynamic computed tomographic myelography is the study of choice for localization of the primary dural defect. Patient symptoms and neurological deficits routinely improve after appropriate surgical intervention. CONCLUSION: Diverse signs and symptoms herald the presentation of ventral spinal meningoceles. Intraoperative, radiographic, and pathological findings are all suggestive of an intradural dissection as the etiology. Hence, they may be more appropriately named “ventral spinal intradural dissecting meningoceles.” Definitive treatment involves identification and obliteration of the dural defect.
Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma
Wadhera, Rishi K. , Kyle, Robert A. , Dispenzieri, Angela , Kumar, Shaji , Rajkumar, S. Vincent , Larson, Dirk R. , Lazarus, Hillard M. , Rajkumar, S Vincent , Dispenzieri, Angela , Wadhera, Rishi K

Mayo Clinic

Blood | July 16, 2011 | Volume: 118 | Issue: 11 | Pages: 2985-2987

10.1182/blood-2011-04-349175 | PMID 21765020 Get It

Abstract During the course of multiple myeloma (MM), new monoclonal proteins of an isotype distinct from the original clone, referred to as secondary monoclonal gammopathy of undetermined significance (MGUS), have been described. We report on the frequency, characteristics, and outcome of secondary MGUS. Of the 1942 patients with MM, 128 (6.6%) developed a secondary MGUS, at a median of 12 months from the diagnosis of MM. The median duration of secondary MGUS was 5.9 months. Secondary MGUS was more common in patients after stem cell transplantation than in those who had not undergone such treatment (22.7% vs 1.6%, P < .001). Overall survival was significantly superior in MM patients who developed secondary MGUS compared with the rest of the cohort (73 vs 38 months, respectively; P < .001). The time of onset and the duration of secondary MGUS, as well as failure to resolve spontaneously, had an effect on overall survival and require further study.
Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis
Kumar, Shaji , Zhang, Mei-Jie , Li, Peigang , Dispenzieri, Angela , Krishnan, Amrita , Wirk, Baldeep , Weiss, Brendan M. , Freytes, César O. , Vogl, Dan T. , Vesole, David H. , Meehan, Kenneth R., Hamadani, Mehdi , Lill, Michael, Majhail, Navneet S. , Wiernik, Peter H. , Nath, Rajneesh , Kamble, Rammurti T., Vij, Ravi , Kyle, Robert A. , Hari, Parameswaran , Milone, Giuseppe , Lonial, Sagar , Maiolino, Ângelo , Lazarus, Hillard M. , Callander, Natalie S. , Gale, Robert Peter , Dispenzieri, Angela , Hamadani, Mehdi , Majhail, Navneet S , Hari, Parameswaran

Mayo Clinic

Blood | June 21, 2011 | Volume: 118 | Issue: 7 | Pages: 1979-1988

10.1182/blood-2011-02-337329 | PMID 21690560 Get It

Abstract Allogeneic hematopoietic cell transplantation in multiple myeloma is limited by prior reports of high treatment-related mortality. We analyzed outcomes after allogeneic hematopoietic cell transplantation for multiple myeloma in 1207 recipients in 3 cohorts based on the year of transplantation: 1989-1994 (n = 343), 1995-2000 (n = 376), and 2001-2005 (n = 488). The most recent cohort was significantly older (53% > 50 years) and had more recipients after prior autotransplantation. Use of unrelated donors, reduced-intensity conditioning and the blood cell grafts increased over time. Rates of acute graft-versus-host (GVHD) were similar, but chronic GVHD rates were highest in the most recent cohort. Overall survival (OS) at 1-year increased over time, reflecting a decrease in treatment-related mortality, but 5-year relapse rates increased from 39% (95% confidence interval [CI], 33%-44%) in 1989-1994 to 58% (95% CI, 51%-64%; P < .001) in the 2001-2005 cohort. Projected 5-year progression-free survival and OS are 14% (95% CI, 9%-20%) and 29% (95% CI, 23%-35%), respectively, in the latest cohort. Increasing age, longer interval from diagnosis to transplantation, and unrelated donor grafts adversely affected OS in multivariate analysis. Survival at 5 years for subjects with none, 1, 2, or 3 of these risk factors were 41% (range, 36%-47%), 32% (range, 27%-37%), 25% (range, 19%-31%), and 3% (range, 0%-11%), respectively (P < .0001).
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease
Lacy, Martha Q. , Allred, Jacob B., Hayman, Suzanne R. , Short, Kristen Detweiler, Dispenzieri, Angela , Kumar, Shaji , Greipp, Philip R., Lust, John A., Russell, Stephen J. , Dingli, David , Zeldenrust, Steven R., Fonseca, Rafaël , Bergsagel, P. Leif , Stewart, A. Keith, Laumann, Kristina, Mandrekar, Sumithra J. , Reeder, Craig B. , Rajkumar, S. Vincent , Gertz, Morie A. , Buadi, Francis K. , Roy, Vivek , Mıkhael, Joseph , Bergsagel, P. Leif , Rajkumar, S Vincent , Dispenzieri, Angela , Russell, Stephen J , Dingli, David , Fonseca, Rafael

Mayo Clinic

Blood | June 20, 2011 | Volume: 118 | Issue: 11 | Pages: 2970-2975

10.1182/blood-2011-04-348896 | PMID 21690557 Get It

Abstract Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2 sequential phase 2 trials using the pomalidomide with weekly dexamethasone (Pom/dex) regimen at differing doses to study the efficacy of this regimen in patients who have failed both lenalidomide and bortezomib. Pomalidomide was given orally 2 or 4 mg daily with dexamethasone 40 mg weekly. Thirty-five patients were enrolled in each cohort. Confirmed responses in the 2-mg cohort consisted of very good partial response (VGPR) in 5 (14%), partial response (PR) in 4 (11%), minor response (MR) in 8 (23%) for an overall response rate of 49%. In the 4-mg cohort, confirmed responses consisted of complete response (CR) in 1 (3%), VGPR in 3 (9%), PR in 6 (17%), MR in 5 (14%) for an overall response rate of 43%. Overall survival at 6 months is 78% and 67% in the 2- and 4-mg cohort, respectively. Myelosuppression was the most common toxicity. This nonrandomized data suggests no advantage for 4 mg over the 2 mg daily. Pomalidomide overcomes resistance in myeloma refractory to both lenalidomide and bortezomib. This trial is registered at http://ClinicalTrials.gov, number NCT00558896.
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma
Madan, Sumit , Lacy, Martha Q. , Dispenzieri, Angela , Hayman, Suzanne R. , Detweiler‐Short, Kristen, Dingli, David , Zeldenrust, Steven R., Lust, John A., Greipp, Philip R., Rajkumar, S. Vincent , Kumar, Shaji , Gertz, Morie A. , Buadi, Francis K. , Rajkumar, S Vincent , Dispenzieri, Angela , Dingli, David

Mayo Clinic

Blood | June 15, 2011 | Volume: 118 | Issue: 7 | Pages: 1763-1765

10.1182/blood-2011-04-350009 | PMID 21673347 Get It

AbstractThe efficacy of retreatment with immunomodulatory drugs (IMiDs) among patients with multiple myeloma who received this class of drugs for initial therapy is unknown. We studied 140 patients who received either thalidomide-dexamethasone (81; 58%) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repeat IMiD (thalidomide [34; 24%] or lenalidomide [106; 76%]) as one of the salvage regimens. A median of 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered before IMiD-based salvage therapy. The median time from diagnosis to repeat exposure to IMiD was 28 months. Among the 113 evaluable patients, 50 (44%) achieved at least a partial response, and 63 (56%) achieved less than a partial response to repeat IMiD. Response rates with lenalidomide retreatment were higher than with repeat administration of thalidomide.